Treatment

• President Trump signed an executive order directing federal regulators to fast-track FDA review of psychedelic drugs including psilocybin and ibogaine for treating depression, anxiety, and PTSD. • The order allocates $50 million in federal funds to states implementing or developing psychedelic treatment programs as part of a federal-state partnership initiative. • Trump highlighted that over 14 million American adults have serious mental illness, with approximately 8 million on prescription medication, framing psychedelics as addressing a national mental health crisis including suicide prevention.

• President issues executive order on April 18, 2026, to speed medical treatments for serious mental illness using psychedelic drugs including ibogaine compounds. • Order highlights clinical studies showing potential for patients with persistent conditions unresponsive to standard therapies. • Directs federal agencies to prioritize research, approvals, and access to innovative mental health interventions nationwide.

President signed executive order directing FDA to expedite review of psychedelic drugs including ibogaineDonald Trump on Saturday announced reforms intended to speed up access to medical research and treatment based on psychedelic drugs.The president signed an executive order directing the federal Food and Drug Administration (FDA) to expedite review of drugs such as ibogaine, a drug that US military veteran groups have said can help treat post-traumatic stress disorder. Continue reading...

Exclusive: ministers consider restricting pesticide-based treatments, which can get into waterways and harm wildlifePet owners across the UK could be banned from buying flea treatment for cats and dogs under new government rules.Ministers have begun an eight-week consultation on letting only veterinary practitioners or pharmacists give out the potent, pesticide-based flea treatments, to ensure “correct usage”. At the moment, the flea and tick treatments can be bought from any pet shop. Continue reading...

• Britney Spears has voluntarily entered a substance abuse treatment facility in Los Angeles more than a month after being arrested on suspicion of driving under the influence. • The pop icon's decision to seek treatment comes as she continues to navigate personal challenges following her conservatorship termination. • The move marks a significant moment in Spears' ongoing recovery journey, with sources close to the singer indicating her commitment to addressing substance abuse concerns.

• FDA has approved an investigational new drug application for synthetic CAR-T (sCAR-T) therapy targeting autoimmune conditions. • The clearance enables clinical trials to test this engineered cell therapy in US patients with refractory autoimmune diseases. • sCAR-T represents a novel approach adapting cancer immunotherapy for immune disorders, potentially offering durable remissions.

• The Advanced Research Projects Agency for Health (ARPA-H) unveiled three potential treatments for osteoarthritis, a condition affecting 32 million Americans, following a $100 million-plus investment over three years announced in 2023. • Research teams are contractually required to begin patient testing within 18 months, marking a shift from traditional federal research timelines. • This initiative addresses the painful joint degeneration disease, with solutions now progressing toward clinical trials amid high prevalence in the US population.